Ionis Pharmaceuticals announced that its pivotal Phase 3 study of zilganersen met its primary endpoint, showing a statistically significant stabilization of gait speed in patients five years of age and older. The data were presented at the American Academy of Neurology (AAN) annual meeting in Chicago on April 21 2026.
The primary endpoint was measured by the 10‑Meter Walk Test (10MWT) at Week 61. Zilganersen 50 mg produced a least‑squares mean difference of 33.3 % in gait speed versus placebo, with a p‑value of 0.041, confirming a clinically meaningful benefit for the rare neurodegenerative disorder known as Alexander disease.
Secondary endpoints, including patient‑, caregiver‑, and clinician‑reported outcome assessments, consistently favored zilganersen over placebo, reinforcing the drug’s potential as a disease‑modifying therapy. The study’s robust design and positive results support a regulatory submission to the U.S. Food and Drug Administration.
Zilganersen carries multiple regulatory designations, including Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease status. The FDA has set a PDUFA action date of September 22 2026, and the company is preparing for a New Drug Application that could bring the first approved treatment for Alexander disease to market.
"These data further build on the promise of zilganersen and reinforce its potential to help transform the treatment landscape for people living with Alexander disease," said Holly Kordasiewicz, Ph.D., executive vice president and chief development officer at Ionis. "If approved, zilganersen will be the first and only treatment for Alexander disease, marking a breakthrough for patients. It would also mark Ionis' first independent commercial launch in neurology, an important milestone that strengthens our neurology franchise and supports our goal to deliver a steady cadence of transformational medicines to people with serious diseases," added CEO Brett Monia, Ph.D.
The positive Phase 3 data advance zilganersen toward regulatory approval and open a new revenue stream for Ionis. The company’s broader neurology portfolio, which includes several RNA‑targeted therapeutics, positions Ionis to capitalize on its growing expertise and to accelerate its transition to a fully integrated commercial‑stage biotechnology firm.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.